摘要
Sheppard Pratt资深迷幻药研究员Matthew Johnson博士探讨了迷幻药的分类方式、作用机制、治疗应用及潜在风险。对话内容涵盖裸盖菇素辅助治疗的临床方案、自我表征的神经科学，以及迷幻药用于抑郁症、成瘾、PTSD和神经损伤的前沿研究。Johnson博士还就微剂量目前缺乏证据支持的问题进行了阐述，同时对高剂量治疗模式表达了乐观态度。
核心要点
- 迷幻药的定义在于其能够深刻改变人的现实感与自我感，横跨多个药理学类别，而非单一药物类型。
- 经典迷幻药（LSD、裸盖菇素、DMT、麦斯卡林）主要作为5-羟色胺2A受体激动剂发挥作用，这使其有别于MDMA和氯胺酮。
- 主要治疗机制似乎是自我表征的持续性改变——瓦解诸如”我是一个抑郁的人”或”我是一个吸烟者”等固化身份模型。
- 在临床环境中，即使在最优准备条件下给予高剂量（约30mg裸盖菇素），仍有大约三分之一的参与者会经历某种程度的”糟糕体验”。
- “顺应”迷幻体验而非抗拒，与更好的结果相关，包括与长期积极转变相关联的超然或神秘体验。
- 微剂量目前缺乏经同行评审的有效证据；研究未显示其对创造力或认知能力有任何提升，部分研究甚至显示时间感知存在轻微损伤。
- MDMA可能特别适合用于PTSD治疗，因为与经典迷幻药相比，它产生深度不稳定体验的可能性更低。
- 早期啮齿动物数据及人类个案报告提示裸盖菇素可能促进neuroplasticity并有助于创伤性脑损伤的恢复，但人体证据目前仍属初步阶段。
详细笔记
什么是迷幻药？
“迷幻药”一词更多是文化概念而非药理学概念，横跨几个截然不同的药物类别。其共同特征是深刻改变人对现实的感知及自我感知的能力。
主要类别包括：
- 经典迷幻药／致幻剂：LSD、裸盖菇素、DMT、麦斯卡林——作为serotonin 2A receptor的激动剂或部分激动剂发挥作用
- 结构上分为色胺类（裸盖菇素、DMT）和苯乙胺类（麦斯卡林）
- NMDA拮抗剂：氯胺酮、PCP、右美沙芬——与经典迷幻药具有重叠的主观体验
- MDMA：自成一类；被称为”内触剂”（touching within）或”共情剂”，因其能增强情感连结与共情能力
经典迷幻药的作用机制
裸盖菇素和LSD作用于serotonin 2A receptor，但5-羟色胺本身并不具有致幻性——这些化合物所触发的特定下游信号通路与正常5-羟色胺活动存在差异。确切的神经科学机制仍在积极研究中。
Johnson博士的功能性框架：迷幻药作为**“预测机器的破坏者”**——人类在很大程度上依赖自上而下的现实模型运作，而迷幻药会瓦解这些模型，包括对自我模型的冲击。
一个关键的感知效应是去习惯化：逆转正常情况下对熟悉刺激停止注意的倾向，使普通物体或感觉变得意义深远。
裸盖菇素治疗的临床方案
筛查阶段：
- 结构化精神科访谈，评估排除性条件
- 主要排除标准：精神病性障碍（schizophrenia）、bipolar disorder躁狂期
- 针对心脏病的心血管筛查
准备阶段：
- 与治疗向导建立治疗关系
- 对可能体验范围（从极度美好到极具挑战性）进行说明性介绍
- 目标：不出现意外；所有情绪反应均受到欢迎
治疗当天：
- 以胶囊形式给予纯裸盖菇素（而非生蘑菇）
- 治疗剂量范围：20–30 mg裸盖菇素
- 尽量减少结构化任务，以保留自然的治疗体验（fMRI环境和认知任务会降低体验的意义感）
- 鼓励参与者顺应体验而非抗拒
- 配备医疗监督：若血压显著升高，可舌下含服硝酸甘油，且不影响迷幻体验
治疗后整合：
- 与向导共同处理体验
- 记忆再巩固与身份转变是持久效果的核心
治疗机制：自我表征与身份转变
跨适应症最为一致的治疗机制似乎是自我表征的改变——即一个人从根本上持有其身份的方式。
举例：
- 吸烟者从”我是一个戒不掉的人”转变为清晰感受到自主能动性：“我可以直接决定不吸烟”
- 癌症患者意识到自己正在主动回避本可享受的活动
- 这些被描述为**“恍然大悟的体验”**——逻辑上已知，但如今以全新的情感分量被真切感受到
这与一种强化的个人能动感相连，有别于单纯被告知应该如何思考。
MDMA用于PTSD
MDMA的dopamine与5-羟色胺联合释放可能使其更适合创伤处理，原因在于：
- 产生深度不稳定或现实崩裂体验的可能性更低
- 能够重新处理创伤记忆并产生持久效果，与记忆再巩固科学相符
- MDMA用于PTSD的研究正在积极推进；裸盖菇素用于PTSD治疗也在开发中
风险与危险
主要风险：
- 既存精神病性障碍（精神分裂症、双相躁狂）——可能遭受严重失稳
- 糟糕体验——即使是心理健康的个体也可能发生，尤其在高剂量或非管控环境下
在最优准备条件下给予30mg裸盖菇素时，约三分之一的参与者在治疗过程中的某一时刻会经历明显的焦虑、恐惧或即将失去理智的感觉。
关键原则：试图抗拒或控制体验会增加糟糕体验的可能性；顺应与更好的结果相关，包括与长期积极转变相关联的神秘体验。
由于感知改变和去习惯化效应，不建议在非监督情况下于动态环境中（如在城市街道行走）使用迷幻药。
微剂量：现有证据
围绕microdosing裸盖菇素的说法包括：
- 改善专注力（被描述为适用于ADHD的更优兴奋剂替代品）
- 改善情绪（被描述为更优的SSRIs替代品）
同行评审研究的实际发现：
- 尚无研究证明其在创造力、认知或持续情绪改善方面有所获益
- 部分研究显示时间估计和时间生产任务存在轻微损伤
- 参与者报告感到轻微飘飘然和轻度认知受损
重要说明： 目前尚无研究对微剂量倡导者推荐的特定循环方案进行建模（例如每3–4天给药，持续数周）。Johnson博士推测，如果有任何获益，最有可能的是通过慢性低水平刺激5-羟色胺2A受体产生适度的抗抑郁效果——原理上与SSRIs相似。
神经损伤与神经可塑性
新兴研究领域：利用裸盖菇素潜在修复来自反复头部撞击（如格斗运动、接触性运动）的脑损伤。
证据基础（早期阶段）：
- 来自David Olsen实验室和Brian Roth实验室等的啮齿动物研究显示，迷幻药化合物可产生多种形式的neuroplasticity
- 运动员个案报告使用迷幻药后认知和记忆有所改善
- 拟议机制：可能与精神科获益背后相同的神经可塑性效应
计划中的研究：
- 有反复头部撞击史且伴有抑郁的退役MMA运动员
- 主要目标：治疗抑郁症
- 探索性目标：通过MRI评估认知改善及灰质变化
涉及概念
- psilocybin
- serotonin 2A receptor
- serotonin
- dopamine
English Original 英文原文
Summary
Dr. Matthew Johnson, a senior psilocybin researcher at Sheppard Pratt, discusses how psychedelics are classified, their mechanisms of action, therapeutic applications, and potential risks. The conversation covers clinical protocols for psilocybin-assisted therapy, the neuroscience of self-representation, and emerging research into psychedelics for depression, addiction, PTSD, and neurological injury. Dr. Johnson also addresses the current lack of evidence supporting microdosing while expressing optimism about high-dose therapeutic models.
Key Takeaways
- Psychedelics are defined by their ability to profoundly alter one’s sense of reality and self, spanning multiple pharmacological classes rather than a single drug type.
- Classic psychedelics (LSD, psilocybin, DMT, mescaline) work primarily as agonists at the serotonin 2A receptor, which distinguishes them from MDMA and ketamine.
- The primary therapeutic mechanism appears to be persistent changes in self-representation — dissolving rigid identity models such as “I am a depressed person” or “I am a smoker.”
- In clinical settings, roughly one-third of participants experience some degree of a “bad trip” even at high doses (around 30mg psilocybin) with optimal preparation.
- “Surrendering” to the psychedelic experience rather than resisting it is associated with better outcomes, including transcendental or mystical experiences linked to long-term positive results.
- Microdosing currently lacks peer-reviewed evidence of benefit; studies show no gains in creativity or cognition, and some show minor impairments in time perception.
- MDMA may be particularly well-suited for PTSD treatment because it produces fewer profoundly destabilizing experiences compared to classic psychedelics.
- Early rodent data and human anecdotes suggest psilocybin may promote neuroplasticity and potentially aid recovery from traumatic brain injury, though human evidence remains preliminary.
Detailed Notes
What Qualifies as a Psychedelic?
The term “psychedelic” is more cultural than pharmacological, spanning several distinct drug classes. The unifying feature is the ability to profoundly alter one’s sense of reality and sense of self.
Major classes include:
- Classic psychedelics / hallucinogens: LSD, psilocybin, DMT, mescaline — act as agonists or partial agonists at the serotonin 2A receptor
- Structurally divided into tryptamines (psilocybin, DMT) and phenethylamines (mescaline)
- NMDA antagonists: Ketamine, PCP, dextromethorphan — overlapping subjective effects with classic psychedelics
- MDMA: Stands in its own class; termed an “entactogen” (touching within) or “empathogen” for its ability to enhance emotional connection and empathy
How Classic Psychedelics Work
Psilocybin and LSD act on the serotonin 2A receptor, but serotonin itself is not psychedelic — the specific downstream signaling pathways triggered by these compounds differ from normal serotonin activity. The exact neuroscience remains under active investigation.
Dr. Johnson’s functional framing: psychedelics act as “prediction machine disruptors” — humans operate largely on top-down models of reality, and psychedelics dissolve those models. This includes challenging the model of the self.
A key perceptual effect is dis-habituation: the reversal of the normal tendency to stop noticing familiar stimuli, causing ordinary objects or sensations to feel profoundly significant.
Clinical Protocol for Psilocybin Therapy
Screening phase:
- Structured psychiatric interviews assessing for disqualifying conditions
- Key exclusions: psychotic disorders (schizophrenia), manic phase of bipolar disorder
- Cardiovascular screening for heart disease
Preparation phase:
- Building therapeutic rapport with session guides
- Didactic explanation of the range of possible experiences (from deeply beautiful to highly challenging)
- Goal: no surprises; all emotional responses are welcomed
Session day:
- Pure psilocybin administered in capsule form (not raw mushrooms)
- Therapeutic dose range: 20–30 mg psilocybin
- Minimal structured tasks to preserve a naturalistic therapeutic experience (fMRI environments and cognitive tasks reduce meaningfulness)
- Participants encouraged to surrender to the experience rather than resist it
- Medical oversight in place: if blood pressure rises significantly, nitroglycerin can be administered sublingually without affecting the psychedelic experience
Post-session integration:
- Processing of experiences with guides
- Reconsolidation of memories and identity shifts are central to lasting effects
Therapeutic Mechanisms: Self-Representation and Identity Change
The most consistent therapeutic mechanism across conditions appears to be changes in self-representation — how a person fundamentally holds their identity.
Examples:
- A smoker shifting from “I’m someone who can’t quit” to experiencing a clear sense of agency: “I can just decide not to smoke”
- Cancer patients realizing they are choosing to avoid activities they could enjoy
- These are described as “duh experiences” — logically known but now felt with new emotional gravity
This connects to a supercharged sense of personal agency, which differs from simply being told to think differently.
MDMA for PTSD
MDMA’s combined dopamine and serotonin release may make it better suited for trauma processing than classic psychedelics because:
- Lower likelihood of profoundly destabilizing or reality-shattering experiences
- Allows reprocessing of traumatic memories with lasting effects, consistent with memory reconsolidation science
- Research with MDMA for PTSD is active; psilocybin for PTSD treatment is also being developed
Risks and Dangers
Primary risks:
- Pre-existing psychotic disorders (schizophrenia, bipolar mania) — can be severely destabilized
- Bad trips — can occur in anyone, even psychologically healthy individuals, especially at high doses or in uncontrolled environments
At 30mg psilocybin with optimal preparation, approximately one-third of participants experience significant anxiety, fear, or a sense of losing their mind at some point during the session.
Key principle: trying to resist or control the experience increases the likelihood of a bad trip; surrender is associated with better outcomes, including mystical experiences tied to long-term positive results.
Psychedelics are not recommended for unsupervised use in dynamic environments (e.g., navigating city streets) due to altered perception and dis-habituation effects.
Microdosing: Current Evidence
Claims around microdosing psilocybin include:
- Improved focus (described as a better version of stimulants for ADHD)
- Improved mood (described as a better version of SSRIs)
What peer-reviewed studies actually show:
- No studies have demonstrated benefits in creativity, cognition, or sustained mood improvement
- Some studies show minor impairments in time estimation and production tasks
- Participants report feeling slightly high and mildly impaired
Important caveat: No studies have yet modeled the specific cycling protocols that microdosing advocates recommend (e.g., dosing every 3–4 days over several weeks). Dr. Johnson speculates the most plausible benefit, if any, would be a modest antidepressant effect via chronic low-level stimulation of the serotonin 2A receptor — similar in principle to SSRIs.
Neurological Injury and Neuroplasticity
Emerging area of interest: using psilocybin to potentially repair brain damage from repetitive head impacts (e.g., combat sports, contact sports).
Evidence base (early stage):
- Rodent studies from labs including David Olsen’s and Brian Roth’s show various forms of neuroplasticity with psychedelic compounds
- Human anecdotes from athletes reporting improved cognition and memory following psychedelic use
- Proposed mechanism: same neuroplastic effects possibly underlying psychiatric benefits
Planned research:
- Retired MMA athletes with history of repetitive head impacts and depression
- Primary aim: treat depression
- Exploratory aim: assess cognitive improvement and gray matter changes via MRI
Mentioned Concepts
- psilocybin
- serotonin 2A receptor
- serotonin
- dopamine